Gilead Sciences : FDA Approves Trodelvy In Pre-treated HR+/HER2- Metastatic Breast Cancer
4/2 08:36
(RTTNews) - Gilead Sciences Inc. (GILD) said that the U.S. Food and Drug Administration approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth facto...